[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001271706A1 - Use of substituted indole compounds for treating breast disorders - Google Patents

Use of substituted indole compounds for treating breast disorders

Info

Publication number
AU2001271706A1
AU2001271706A1 AU2001271706A AU7170601A AU2001271706A1 AU 2001271706 A1 AU2001271706 A1 AU 2001271706A1 AU 2001271706 A AU2001271706 A AU 2001271706A AU 7170601 A AU7170601 A AU 7170601A AU 2001271706 A1 AU2001271706 A1 AU 2001271706A1
Authority
AU
Australia
Prior art keywords
treating breast
substituted indole
indole compounds
breast disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271706A
Inventor
Christopher Paul Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001271706A1 publication Critical patent/AU2001271706A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001271706A 2000-07-06 2001-06-29 Use of substituted indole compounds for treating breast disorders Abandoned AU2001271706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21618300P 2000-07-06 2000-07-06
US60/216,183 2000-07-06
PCT/US2001/020895 WO2002003986A2 (en) 2000-07-06 2001-06-29 Use of substituted indole compounds for treating breast disorders

Publications (1)

Publication Number Publication Date
AU2001271706A1 true AU2001271706A1 (en) 2002-01-21

Family

ID=22806048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271706A Abandoned AU2001271706A1 (en) 2000-07-06 2001-06-29 Use of substituted indole compounds for treating breast disorders

Country Status (3)

Country Link
US (1) US20020016318A1 (en)
AU (1) AU2001271706A1 (en)
WO (1) WO2002003986A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006116157A2 (en) * 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
CN104945303B (en) * 2015-06-15 2017-09-29 浙江工业大学 preparation method of 3-alkenyl indole compound
BR112018006121B1 (en) 2015-10-01 2024-01-23 Olema Pharmaceuticals, Inc TETRAHYDRO-1H-PYRIDO[3,4-b]INDOL COMPOUNDS, COMPOSITIONS COMPRISING SAID COMPOUNDS AND USES THEREOF
HUE061065T2 (en) 2015-12-09 2023-05-28 The Board Of Trustees Of The Univ Benzothiophene-based selective estrogen receptor downregulators
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
BR112018077136A2 (en) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. compound, and methods for treating a disorder associated with abnormal cell proliferation and for reducing the effect of chemotherapy on healthy cells.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (en) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド Combination therapy for cancer treatment
TW201835064A (en) 2017-02-10 2018-10-01 美商G1治療公司 Benzothiophene estrogen receptor modulators
EP4455146A3 (en) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
MX2022007659A (en) 2019-12-20 2022-07-19 C4 Therapeutics Inc Isoindolinone and indazole compounds for the degradation of egfr.
IL295709A (en) 2020-03-05 2022-10-01 C4 Therapeutics Inc Compounds for targeted degradation of brd9
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
KR20250055538A (en) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Compounds for modulating RET proteins
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
NZ314601A (en) * 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof

Also Published As

Publication number Publication date
US20020016318A1 (en) 2002-02-07
WO2002003986A3 (en) 2002-08-08
WO2002003986A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001271706A1 (en) Use of substituted indole compounds for treating breast disorders
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
IL138129A (en) Composition for therapy of estrogen-associated disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU2001272852A1 (en) Composition for the treatment of migraine
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
IL160043A0 (en) Process for the preparation of indole derivatives
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU2001239510A1 (en) Treatment of renal disorders
AU2002364711A1 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
AU7388101A (en) Indole derivatives useful for the treatment of cns disorders
PL347329A1 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
AU8173801A (en) Indole derivatives useful for the treatment of cns disorders
AU8339301A (en) Compounds for the treatment of addictive disorders
AU3899100A (en) Treatment of hyperactivity disorders
IL153254A0 (en) Indole derivatives useful for the treatment of cns disorders
SI1468686T1 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2000272704A1 (en) Use of compounds for the treatment of obesity
GB9918058D0 (en) Compound for treatment of gi disorders
AU2002218335A1 (en) Combination therapy for treatment of serotonergic disorders